Nova Eye Medical Limited (EYE) Fair Value & Analysis
Healthcare · AU · Market cap A$33.3M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.3000 to A$0.0200 (−93.3%) since Jun 24, 2026. Share price −8.7% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0971 – A$0.1894 · fair‑value band A$0.0100 – A$0.0200 · the A$0.1020 price screens above the A$0.0200 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Nova Eye Medical Limited (EYE) currently trades at A$0.1020, while our model-based Fair Value estimate is A$0.0200 — implying the stock looks roughly 80.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Nova Eye Medical Limited generated revenue of A$33.1M at a net margin of -21.3%. Revenue grew 29.3% year over year. It earns a return on equity of -42.4%. The balance sheet holds a net cash position of A$2.0M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nova Eye Medical Limited reported revenue of A$29.3M in FY2025 versus A$13.4M in FY2021, a compound +21.6%/yr. Reported net income was −A$9.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nova Eye Medical Limited (EYE) undervalued?
What is the fair value of EYE?
What is the quality score of EYE?
What is the revenue of Nova Eye Medical Limited (EYE)?
What is the net profit margin of EYE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.